Overview

A Phase II Clinical Study to Evaluate the Efficacy and Safety of Flazoparib Combined With Temozolomide After the Completion of Standard Concurrent Chemoradiotherapy (CCRT) in Newly Diagnosed Glioblastoma

Status:
NOT_YET_RECRUITING

Trial end date:
2027-07-31

Target enrollment:

Participant gender:

Summary

A Phase II clinical study is planned to evaluate the efficacy and safety of fluzoparib combined with temozolomide in newly diagnosed glioblastoma patients after completing standard concurrent chemoradiotherapy (CCRT), explore the effectiveness and safety of this regimen, and find a better treatment option for glioblastoma patients

Phase:

PHASE2

Details

Lead Sponsor:

Tongji Hospital

Treatments:

fluzoparib
Temozolomide